CompletedNot Applicable

Coronary Artery Disease Screening in Kidney Transplant Candidates

Canada144 participantsStarted 2014-11

Plain-language summary

Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown. Currently patients undergo annual testing; however, screening for CAD may increase morbidity and mortality by: 1. exposing patients to the risk of angiography and revascularization procedures 2. delaying or excluding patients from life saving transplantation. Before proceeding with a definitive study to determine whether screening is necessary, feasibility will be determined in this pilot study.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age greater than 18 years * active on the deceased donor transplant waiting list Exclusion Criteria: * patients not expected to require further screening for CAD prior to transplantation by the current standard of care. For example, a diabetic patient recently screened for CAD and expected to be transplanted \<12 months from the start of the study would not require further screening according to current guidelines and would be ineligible * patients with signs or symptoms suggestive of active cardiac disease such as unstable coronary syndromes, de-compensated heart failure, uncontrolled arrhythmia, and severe valvular heart disease * patient who have been put "on hold" for transplantation due to a medical problem (e.g. an infection) * prior extra-renal transplant recipients * multi-organ transplant candidates (e.g. kidney pancreas transplant candidates) * patients with a planned living donor transplant * patients unable to provide informed consent

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Participants Adhering to the Expected Number of Screening Tests

Timeframe: Up to 27 months

Enrolment Rates

Timeframe: Measured after enrolment period of 6 months

Consent Rate

Timeframe: Measured after enrolment period of 6 months

Trial details

NCT IDNCT02082483

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-02

Results submitted2019-11-27

View on ClinicalTrials.gov More End Stage Renal Disease trials